U.S. Patent for Bioelectric Expression of Klotho, a Key Longevity and Disease-Fighting Protein Issued to Leonhardt Ventures
October 20 2022 - 05:04PM
Leonhardt Ventures, LLC is pleased to announce the United
States Patent and Trademark Office (USPTO) has issued U.S. Patent
No. 11,471,686 covering bioelectric stimulation control of
increasing Klotho, a protein must known for muscle regeneration and
other powerful anti-aging properties. More than 3,000 papers have
been published describing a clear connection between low Klotho
levels and nearly all age-related ailments and major diseases,
including heart and cardiovascular disease, muscle atrophy, kidney
failure, cancer, brain disorders, high blood pressure and diabetes.
"This Klotho patent adds significant support to
our goal mission to help people live longer and healthier lives.
Adequate Klotho levels may be a critical factor in healthy aging
and disease prevention. In landmark studies, mice deficient in
Klotho exhibited accelerated aging and died 30% sooner than mice
with normal Klotho levels. Mice receiving supplemental Klotho lived
30% longer with fewer aging-related ailments. In recent clinical
studies, we have demonstrated up to a 150% increase in circulating
Klotho with only two 45-minute bioelectric stimulation sessions a
week for four weeks. We are conducting additional well controlled
clinical studies to gather data to further demonstrate the safety
and efficacy of this technology," stated Howard J. Leonhardt,
Executive Chairman & CEO of Leonhardt Ventures, LLC.
This Klotho IP and technology has been licensed
for use with numerous organ specific therapeutic candidate
innovations, including the following:
- Heart and Cardiovascular applications include
heart, heart valve, and aorta regeneration, and high blood pressure
management.
- Brain and Neurological
applications include treatments for depression, memory loss,
addiction, spinal cord injury, stroke, and traumatic brain
injury.
- Cosmetic and Personal Care applications
include skin and hair regeneration, accelerated teeth straightening
and stabilization, and treatment of sleep apnea and breathing
disorders, breast augmentation, and erectile
dysfunction.
- Major Organ Regeneration applications include
muscle building and regeneration and treatments for bladder
dysfunction, kidney failure, liver failure, lung recovery, covid
recovery, vision and hearing recovery, and knee joint
pain.
- Cancer Klotho has been shown in some
pre-clinical studies to exhibit tumor suppression activity. Our
portfolio startup CanceCell is developing Klotho stimulation and
other bioelectric and biologic treatments for cancer and has
received 10 issued U.S. patents already.
The company is developing
KlothoYears, a program to provide access to Klotho
testing and education on ways to increase Klotho, and to provide
participants with a comparison of their level to normal values for
their age, gender, and other demographics. The program is in early
beta launch research phase in only selected regions at this time
and with plans in place to fully launch nationwide in the USA some
time in 2023 with a tested full logistics system in
place.
In 2021 Leonhardt Ventures LLC announced it
purchased an exclusive license to intellectual property for
KLOTHO EXPRESSING MESENCHYMAL STEM
CELLS intended to be used in combination with its
bioelectric IP for a wide range of longevity and wellness
applications. Our research team believes this combination
represents the potential to be a potent therapy for patients most
in need.
About Leonhardt Ventures LLC:
Founded in 1982 by Howard J. Leonhardt, Leonhardt
Ventures LLC (formerly HJ Leonhardt & Co.) , located in Mission
Viejo, CA, is a venture creation lab, product invention development
laboratory, venture fund, and angel mentoring network. The
Leonhardt team introduced the PolyCath TM line of cardiovascular
balloon catheters in the 1980s, the TALENT TM (Taheri-Leonhardt)
stent graft, StentValve, ProCell stem cell delivery catheters,
PENSIL intravascular lung, RadiCath electromagnetic radiation
delivery catheters, and bioelectric stimulators for improving blood
flow in the 1990s. In 1987 Howard Leonhardt began a dialogue
and collaboration with Dr. Robert. O. Becker Author of The Body
Electric which influenced the forward pathway of the company. Since
then, the company has primarily focused on the convergence of
bioelectrics and biologics for longevity and wellness including
tissue organ repair and regeneration. In 1989 the team working with
Dr. Race Kao and Dr. George McGovern published their first paper on
heart muscle regeneration with muscle stem cells (satellite cells)
in The Physiologist. In 1999 working with Dr. Shinichi Kanno
the team published their first bioelectric regeneration paper in
CIRCULATION. In 2001, the Leonhardt team led the landmark
first-ever non-surgical repair of a human heart with muscle stem
cells working with Dr. Doris Taylor, Dr. Warren Sherman and Dr.
Patrick Serruys. In 2019 Leonhardt led a team that completed
the first ever percutaneous aortic stent based circulatory assist
pump placement working with Dr. Adrian Ebner. More than
600,000 patients have have been treated with Leonhardt medical
device and biotechnology inventions since 1988. The Leonhardt
team has over 700 patent claims issued, pending, in process,
optioned or licensed. A partial listing is available at
https://patents.justia.com/inventor/howard-j-leonhardt. Leonhardt’s
Launchpads founded in 2008 is the innovation and startup launch
accelerator arm of Leonhardt Ventures LLC with an R&D lab at
University Lab Partners at UCI Research Park, 5270 California Ave.,
Irvine, CA 92617. Leonhardt's Launchpad's portfolio of
startups and innovations receives business mentoring and a variety
of other support services from Cal-X Star Business Accelerator,
Inc.
About Lionheart Health, Inc.
: Lionheart Health, Inc. founded in 2021 in
beta launch phase, is a sales, marketing, and distribution arm of
Leonhardt Ventures LLC focused on commercializing disruptive
technologies for longevity and wellness. They plan to launch
several products in the U.S. and other markets beginning in 2023.
These include;
- BodStim™ is a bioelectric bodysuit that
augments muscle building exercise and increases Klotho
- SkinStim™ bioelectric skin rejuvenation
- HairCell™ bioelectric hair rejuvenation
- ErectiStim™ by MyoStim ED bioelectric
treatment for men's sexual wellness.
The company is working in partnership with
established OEM manufacturers with FDA 510(k) market
clearances for multiple indications, including muscle stimulation,
pain/inflammation relief, and circulation improvement. The company
also intends to launch a chain of Longevity and Wellness MedSpas
based on its proprietary core technologies in 2024.
PUBLIC RELATIONS MEDIA CONTACT: Brian
HardyLeonhardt Ventures LLC Tel: (424) 291-2133Email:
brian@fizzpopmedia.com
COMPANY CONTACT: Howard J. Leonhardt
Executive Chairman and CEOEmail:
howard@leonhardtventures.com
Related Links:
- Leonhardt Ventures Announces Launch of Research Program
Using Patent Pending Klotho Expressing Mesenchymal Stem Cells for
Multiple Applications in Combination with Bioelectric Protein
Expressions
- Klotho Anti-Aging Super Powers?
- BodStim – taking longevity wearables to the next
level
- Klotho: The Super-Antioxidant You've Never Heard
of
- Klotho: The protein that could extend your healthspan
and lifespan
Headquarters Office: Leonhardt Ventures
LLC, 1 Kent Court, Mission Viejo, CA 92694
Main Web site:
www.leonhardtventures.com
Research and Development LabLeonhardt’s Launchpads powered
by Cal-X Stars Business Accelerator, Inc. @ University Lab
Partners UCI Research Park 5270 California AvenueIrvine, CA
92617For the original news story, please
visit https://www.prdistribution.com/news/u-s-patent-for-bioelectric-expression-of-klotho-a-key-longevity-and-disease-fighting-protein-issued-to-leonhardt-ventures/9355049
- U.S. Patent for Bioelectric Expression of Klotho, a Key
Longevity and Disease-Fighting Protein Issued to Leonhardt
Ventures
- U.S. Patent for Bioelectric Expression of Klotho, a Key
Longevity and Disease-Fighting Protein Issued to Leonhardt
Ventures
Full Name : Howard J. Leohardt
Company : Leonhardt Ventures LLC
Phone Number : (424) 291-2133
Website : https://www.leonhardtventures.com
Email : howard@leonhardtventures.com